[1] Floreani A, Caroli D, Variola A, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int, 2011,31:361-368.
[2] Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology, 2009,50:291-308.
[3] Gong Y, Frederiksen SL, Gluud C. D-penicillamine for primary biliary cirrhosis. Cochrane Database Syst Rev, 2004:CD004789.
[4] Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology, 2002,122:652-658.
[5] Vleggaar FP, van Buuren HR, Zondervan PE, et al. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut, 2001,49:276-281.
[6] Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology, 1985,89:1084-1091.
[7] Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology, 2000,32:1196-1199.
[8] Liermann GRF, Evangelista GC, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology, 2001,33:22-27.
[9] Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology, 1997,113:884-890.
[10] Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology, 2005,128:297-303.
[11] Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol, 2006,101:1529-1538.
[12] Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology, 2013,144:560-569.e7; quiz e13-14.
[13] Balasubramaniam K, Grambsch PM, Wiesner RH, et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology, 1990,98:1567-1571.
[14] Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology, 2002,123:1044-1051.
[15] Mitchison HC, Lucey MR, Kelly PJ, et al. Symptom development and prognosis in primary biliary cirrhosis: a study in two centers. Gastroenterology, 1990,99:778-784.
[16] Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet, 1996,348:1399-1402.
[17] Springer J, Cauch-Dudek K, O'Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol, 1999,94:47-53.
[18] Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut, 2004,53:865-870.
[19] Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol, 1994,20:707-713.
[20] Vleggaar FP, van Buuren HR. No prognostic significance of antimitochondrial antibody profile testing in primary biliary cirrhosis. Hepatogastroenterology, 2004,51:937-940.
[21] Klein R, Pointner H, Zilly W, et al. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: a prospective study on 200 patients followed for 10 years. Liver, 1997,17:119-128.
[22] Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis, 2005,25:298-310.
[23] Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology, 2007,45:118-127.
[24] Corpechot C, Poujol-Robert A, Wendum D, et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int, 2004,24:187-193.
[25] Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut, 1979,20:137-140.
[26] Bonnand AM, Heathcote EJ, Lindor KD, et al. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology, 1999,29:39-43.
[27] Roll J, Boyer JL, Barry D, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med, 1983,308:1-7.
[28] Rydning A, Schrumpf E, Abdelnoor M, et al. Factors of prognostic importance in primary biliary cirrhosis. Scand J Gastroenterol, 1990,25:119-126.
[29] Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology, 1985,89:1084-1091.
[30] Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology, 1989,10:1-7.
[31] Kim WR, Wiesner RH, Poterucha JJ, et al. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl, 2000,6:489-494.
[32] Patanwala I, McMeekin P, Walters R, et al. A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score. J Hepatol, 2013,59:327-335.
[33] Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver, 1999,19:115-121.
[34] Levy C, Zein CO, Gomez J, et al. Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol, 2007,5:803-808.
[35] Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology, 2012,56:1409-1417.
[36] Suzuki A, Lymp J, Donlinger J, et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol, 2007,5:259-264.
[37] Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology, 2009,136:1281-1287.
[38] Jones DE, Metcalf JV, Collier JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology, 1997,26:1138-1142.
[39] Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology, 2013,57:1942-1949.
[40] Kuiper EM, Hansen BE, Adang RP, et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol, 2010,22:1495-1502. |
